# Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in Healthy Adult Subjects.

> **NCT06642987** · PHASE1 · COMPLETED · sponsor: **Hanlim Pharm. Co., Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Gastric Ulcer

## Interventions

- **DRUG:** Vonoprazan Test 20mg
- **DRUG:** Vonoprazan Reference 20mg

## Key facts

- **NCT ID:** NCT06642987
- **Lead sponsor:** Hanlim Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-23
- **Primary completion:** 2023-11-03
- **Final completion:** 2024-02-23
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06642987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06642987, "Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in Healthy Adult Subjects.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06642987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*